Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate ...

Breast cancer remains the most common cancer among women globally, with cases expected to surge by 2050. Researchers analyzed ...

PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...

Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody ...

Older age, White race, men, and Crohn disease were among the patient-specific factors associated with a greater risk for any skin cancer. The retrospective cohort study compared patients with ...

Asian American women with breast cancer had higher survival rates than white women, though outcomes differed across ethnic ...

Therapeutic cancer vaccines have the potential to induce durable and tumor-specific immune responses in addition to the widely used immune checkpoint blockade therapies. These vaccines aim to ...

Some of the philanthropic foundations that fund ICIJ have programs or campaigns advocating for reform of the pharmaceutical ...

How Merck keeps the price of its blockbuster cancer drug sky-high, shutting out patients and straining health care systems ...

Updated findings from the phase 3 ROSELLA trial (NCT05257408) showed that combining relacorilant (Lifyorli) with ...

Lung cancer risk is strongly predicted by follow-up low-dose computed tomography (LDCT) scans showing new or growing nodules.

As of April 8, 2026, analyst sentiment toward Allogene Therapeutics, Inc. (NASDAQ:ALLO) remains bullish, with 85% of analysts ...